Laddu Gopal scraps ₹30 cr rights issue after BSE approval failure
The nano-cap, worth just ₹6 cr, had sought to raise five times its market capitalisation. Now it's back to square one without equity funding.
What's new
- Rights issue of ₹30 cr withdrawn after failing to secure BSE in-principle approval.
- Proposed size was five times the company's market capitalisation of ₹6 cr.
- No alternative fundraising plan announced; nano-cap left without equity funding.
Why this matters
Withdrawal removes the threat of massive dilution, but for a company with negative PAT growth and minimal cash flow, the loss of planned capital could stunt any expansion. The failure to secure exchange approval raises governance and credibility questions.
What we're watching
- Whether Laddu Gopal presents an alternative funding plan.
- Impact on the stock price given the mismatch between planned raise and market cap.
- Any subsequent regulatory or exchange comments.
The full read
Laddu Gopal wanted ₹30 crore — five times its market cap of ₹6 crore. It couldn't get BSE approval. That's that. On June 17, the board scrapped the plan. The withdrawal removes the threat of massive dilution, but a nano-cap with -102.6% PAT growth had been counting on that capital. With no alternative funding, the firm is back to negligible internal accruals. The open question is whether the exchange's silence signals deeper doubts about viability.
Questions answered
- Why did Laddu Gopal's rights issue fail?
- The company failed to secure in-principle approval from BSE within the required timeline, leading to the board's decision to scrap the issue.
- How large was the proposed rights issue relative to the company?
- At ₹30 cr, the rights issue was five times the company's market capitalisation of ₹6 cr, a highly disproportionate ratio.
- What does this mean for the company's finances?
- Laddu Gopal loses a planned equity infusion, and with trailing PAT growth of -102.6%, it may face constraints on working capital or expansion plans.
- Will the stock price be affected?
- The removal of massive dilution could offer some support, but the failure to secure exchange approval and lack of alternative funding may weigh on sentiment.
- What is the company's current financial health?
- With a market cap of ₹6 cr, P/E of 15.2, ROE of 1.9%, and negative PAT growth, it is a nano-cap with weak profitability metrics.